The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Notes to Consolidated Financial Statements
March 31, 2023 and 2022
(Unaudited)
NOTE 1 - NATURE OF OPERATIONS, BASIS OF PRESENTATION
AND GOING CONCERN
Unless otherwise indicated, any reference to “the
Company”, “our company”, “we”, “us”, or “its” refers to IIOT-OXYS, Inc., a Nevada
corporation, and as applicable to its wholly-owned subsidiaries, OXYS Corporation, a Nevada corporation, and HereLab, Inc., a Delaware
corporation.
IIOT-OXYS, Inc., a Nevada corporation (the “Company”)
was established for the purpose of designing, building, testing, and selling Edge Computing Systems for the Industrial Internet. The Company
is currently devoting substantially all its efforts in identifying, developing and marketing engineered products, software and services
for applications in the Industrial Internet which involves collecting and processing data collected from a wide variety of industrial
systems and machines.
The Company was incorporated in the state of New
Jersey on October 1, 2003 under the name of Creative Beauty Supply Corporation and commenced operations as of January 1, 2004. On November
30, 2007, the Board of Directors approved a plan to dispose of its wholesale and retail beauty supply business. On May 18, 2015, the Company
changed its name to Gotham Capital Holdings. From January 1, 2009 until July 28, 2017, the Company had no operations. On March 16, 2017,
the Board of Directors approved a name change to “IIOT-OXYS, Inc.” and authorized a change of domicile from New Jersey to
Nevada.
Impact of COVID-19
The global COVID-19 pandemic continues to present
uncertainty and unforeseeable risks to the Company’s operations and business plan. The Company has closely monitored recent developments,
including the lifting of COVID-19 safety measures, the spread of new strains or variants of the coronavirus (such as the Delta and Omicron
variants), and supply chain and labor shortages. Thus, the full impact of the COVID-19 pandemic on the business and operations remains
uncertain and will vary depending on the pandemic’s future impact on the third parties with whom the Company does business, as well
as any legal or regulatory consequences resulting therefrom. The Company has been following the recommendations of health authorities
to minimize exposure risk for its team members and may take further actions that alter our operations, including any required by federal,
state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom the Company
does business.
Basis of Presentation
The accompanying financial statements have been
prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include
the accounts of the Company. The financial statements and accompanying notes are the representations of the Company’s management,
who is responsible for their integrity and objectivity. In the opinion of the Company’s management, the financial statements reflect
all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.
Going Concern
The accompanying condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements,
the Company has suffered continuing operating losses, has a working capital deficit of $1,741,781, used cash flows in operating activities
of $61,289, and has an accumulated deficit of $9,485,307 as of March 31, 2023. These factors, among others, raise a substantial doubt
about the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced
to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification
of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern.
Management believes that the Company will be able
to achieve a satisfactory level of liquidity to meet the Company’s obligations for the next twelve months by generating cash through
additional borrowings and/or sale of equity securities, as needed. However, there can be no assurance that the Company will be able to
generate sufficient liquidity to maintain its operations. The financial statements do not include any adjustments that might result from
the outcome of these uncertainties.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
The following summary of significant accounting
policies of the Company is presented to assist in the understanding of the Company’s financial statements. These accounting policies
conform to GAAP in all material respects and have been consistently applied in preparing the accompanying consolidated financial statements.
Interim Financial Statements
The accompanying unaudited interim financial statements
and related notes have been prepared in accordance with GAAP for interim financial information, and in accordance with the rules and regulations
of the United States Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X.
Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited
interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in
the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily
indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with
the audited financial statements of the Company for the year ended December 31, 2022.
Principles of Consolidation
The consolidated financial statements for March
31, 2023 and 2022, respectively, include the accounts of Company, and its wholly-owned subsidiaries OXYS Corporation and HereLab, Inc.
All significant intercompany balances and transactions have been eliminated.
Reclassifications
Certain amounts in the prior periods presented
have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously
reported net income.
Use of Estimates
The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued
liabilities and payable to related parties. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there
are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents
The Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents. The Company did not have any cash equivalents as
of March 31, 2023 and December 31, 2022. The Company reported a cash balance of $25,158 and $33,336 as of March 31, 2023 and December
31, 2022, respectively.
Accounts Receivable and Allowance for Doubtful
Accounts
Trade accounts receivable are carried at original
invoice amount less an estimate made for doubtful accounts. The Company determines the allowance for doubtful accounts by identifying
potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts. Trade accounts
receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income
when received. The Company recorded accounts receivable of $9,893 and $28,941 at March 31, 2023 and December 31, 2022, and no allowance
for doubtful accounts was deemed necessary as of March 31, 2023 and December 31, 2022, respectively.
Long-Lived Assets
The Company regularly reviews the carrying value
and estimated lives of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to the carrying
value or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability
to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets
to the Company’s business objectives.
Definite-lived intangible assets are amortized
on a straight-line basis over the estimated periods benefited and are reviewed when appropriate for possible impairment.
Basic and Diluted Earnings (Loss) Per Common Share
The Company computes earnings (loss) per share
in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”), ASC 260, “Earnings
per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face
of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted
average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares
outstanding during the period using the treasury stock method and convertible note and preferred stock using the if-converted method.
In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from
the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Revenue Recognition
The Company’s revenue is derived primarily
from providing services under contractual agreements. The Company recognizes revenue in accordance with ASC Topic No. 606, Revenue
from Contracts with Customers (“ASC 606”) which was adopted on January 1, 2018.
According to ASC 606, the Company recognizes revenue
based on the following criteria:
|
· |
Identification of a contract or contracts, with a customer. |
|
· |
Identification of the performance obligations in the contract. |
|
· |
Determination of contract price. |
|
· |
Allocation of transaction price to the performance obligation. |
|
· |
Recognition of revenue when, or as, performance obligation is satisfied. |
The Company used a practical expedient available
under ASC 606-10-65-1(f)4 that permits it to consider the aggregate effect of all contract modifications that occurred before the beginning
of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating
the transaction price to the satisfied and unsatisfied performance obligations.
The Company has elected to treat shipping and
handling activities as cost of sales. Additionally, the Company has elected to record revenue net of sales and other similar taxes.
Concentration of Credit Risk
Financial instruments that potentially expose
the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company’s
policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure.
Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”), up to $250,000. At
March 31, 2023 and December 31, 2022, the Company had no amounts in excess of the FDIC insurance limit.
Fair Value of Financial Instruments and Fair
Value Measurements
ASC 820, “Fair Value Measurements and
Disclosures”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used
to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of
input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure
fair value:
Level 1 applies to assets or liabilities for which
there are quoted prices in active markets for identical assets or liabilities.
Level 2 applies to assets or liabilities for which
there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities
in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less
active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated
by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially
the full term of the asset or liability.
Level 3 applies to assets or liabilities for which
there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or
liabilities.
The Company’s consolidated financial instruments
consist of cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued liabilities, notes payable and
related parties payable. The Company believes that the recorded values of all the financial instruments approximate their current fair
values because of their nature and respective maturity dates or durations.
Income Taxes
The Company accounts for income taxes using the
asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provide that
deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial
reporting and tax basis of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities
are measured using the currently enacted tax rates and laws. The Company records a valuation allowance to reduce deferred tax assets to
the amount that is believed more likely than not to be realized.
The Company follows the provisions of ASC 740-10,
“Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions
taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position
taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of
a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination.
Convertible Debt and Convertible Preferred
Stock
When the Company issues convertible debt or convertible
preferred stock, it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether
the instrument should be classified as a liability under ASC 480, Distinguishing Liabilities from Equity, and second whether the
conversion feature should be accounted for separately from the host instrument. A conversion feature of a convertible debt instrument
or certain convertible preferred stock would be separated from the convertible instrument and classified as a derivative liability if
the conversion feature, were it a standalone instrument, meets the definition of an “embedded derivative” in ASC 815, Derivatives
and Hedging. Generally, characteristics that require derivative treatment include, among others, when the conversion feature is not
indexed to the Company’s equity, as defined in ASC 815-40, or when it must be settled either in cash or by issuing stock that is
readily convertible to cash. When a conversion feature meets the definition of an embedded derivative, it would be separated from the
host instrument and classified as a derivative liability carried on the consolidated balance sheet at fair value, with any changes in
its fair value recognized currently in the consolidated statements of operations.
Effective January 1, 2022, we early adopted ASU
2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
using the modified retrospective method of adoption. ASU 2020-06 simplifies the accounting for convertible instruments by removing certain
separation models in Subtopic 470- 20, Debt—Debt with Conversion and Other Options, for convertible instruments. Under ASU
2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments with conversion features
that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial
premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured
at its amortized cost as long as no other features require bifurcation and recognition as derivatives. By removing those separation models,
the interest rate of convertible debt instruments typically will be closer to the coupon interest rate when applying the guidance in Topic
835, Interest. We now account for our Convertible Notes as single liabilities measured at amortized cost. As a result, the adoption of
the guidance had a material impact on the consolidated financial statements and accompanying notes, resulting in adjustments of $371,125,
$313,976 and $57,149 to the opening balance of additional paid-in capital, retained earnings, and long-term debt, respectively, as of
January 1, 2022. We have updated our debt note (Note 5) with additional and modified disclosures as required by the standard upon
adoption.
Recent Accounting Pronouncements
In December 2019, the Financial Accounting Standards
Board issued Accounting Standards Update (“ASU”) ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the
Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes
certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application.
This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and interim
periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company has adopted this guidance and
it does not have any material impact on its consolidated financial statements.
Other accounting standards that have been issued
or proposed by FASB and do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its financial condition, results of operations, cash flows or disclosures.
NOTE 3 - NOTE RECEIVABLE
On April 4, 2022, the Company executed an unsecured
convertible promissory note with the principal sum of $200,000 (“Note”) with a company incorporated under the laws of the
Province of British Columbia. The Note bears an original issuance discount of $7,500 and matures on April 4, 2024. The interest on the
Note will begin to accrue at the rate of 10% per annum from the date of the Note, and will continue to accrue on the outstanding principal
until the entire balance is paid or converted into shares of common stock equal to 3.23% of the fully diluted share capital of the borrower
on the conversion date. The terms of the Note require the borrower to prepay (i) within 30 days of April 4, 2022, the first twelve months
of interest totaling $20,000, and (ii) within six months of April 4, 2022, the interest for the second twelve months under the Note totaling
$20,000. The Company will have the right, at its option on the maturity date, to convert all the principal sum into the common stock equal
to 3.23% of the fully diluted share capital of the borrower as of the conversion date. On April 4, 2022, the Company advanced to the borrower
$192,500 cash and recorded an original issuance discount on note receivable of $7,500. On April 21, 2022, the Company received $20,000
as prepaid interest from the borrower. The Company recorded interest income earned on the Note of $5,856 for the three months ended March
31, 2023. The Company recorded unearned interest of $2,219 and $5,151, and unamortized original debt discount of $3,791 and $4,716 at March
31, 2023 and December 31, 2022, respectively.
NOTE 4 - INTANGIBLE ASSETS
The Company’s intangible assets comprise
of intellectual property revolving around their field tests, sensor integrations, and board designs. Intangible assets, net of amortization
at March 31, 2023 and December 31, 2022 amounted to $236,379 and $248,585, respectively.
Schedule of intangible assets | |
| | |
| |
| |
March 31,
2023 | | |
December 31, 2022 | |
Intangible Assets | |
$ | 495,000 | | |
$ | 495,000 | |
Accumulated amortization | |
| (258,621 | ) | |
| (246,415 | ) |
Intangible Assets, net | |
$ | 236,379 | | |
$ | 248,585 | |
The Company determined that none of its intangible
assets were impaired as of March 31, 2023 and December 31, 2022, respectively, Amortizable intangible assets are amortized using the straight-line
method over their estimated useful lives of ten years. Amortization expense of finite-lived intangibles was $12,205 for the three months
ended March 31, 2023 and 2022, respectively.
The following table summarizes the Company’s
estimated future amortization expense of intangible assets with finite lives as of March 31, 2023:
Schedule of future amortization | |
| |
| |
Amortization Expense | |
2023 (Remainder of the year) | |
$ | 37,295 | |
2024 | |
| 49,500 | |
2025 | |
| 49,500 | |
2026 | |
| 49,500 | |
2027 | |
| 49,500 | |
Thereafter | |
| 1,084 | |
Total | |
$ | 236,379 | |
NOTE 5 - COMMITMENTS AND CONTINGENCIES
In prior years, the Company entered into consulting
agreements with one director, three executive officers, and one engineer of the Company, which include commitments to issue shares of
the Company’s common stock from the Company’s 2017 Stock Incentive Plan and 2019 Stock Incentive Plans. All the consulting
agreements have been terminated and shares have been issued in conjunction with the related separation agreements. According to the terms
of the agreements, 3,547,788 shares were vested and issued per the Company’s 2017 Stock Incentive Plan as of March 31, 2023 and
December 31, 2022, and 3,080,000 shares and 2,980,000 shares were vested and issued per the Company’s 2019 Stock Incentive Plan
as of March 31, 2023 and December 31, 2022, respectively.
In the event that the agreement is terminated
by either party pursuant to the terms of the agreement, all unvested shares which have been earned shall vest on a pro-rata basis as of
the effective date of the termination of the agreement and all unearned, unvested shares shall be terminated. The value of the shares
was assigned at fair market value on the effective date of the agreement and the pro-rata number of shares earned was calculated and amortized
at the end of each reporting period.
On March 18, 2022, the Company adopted 2022 Stock
Incentive Plan and reserved for issuance 20,000,000 shares of common stock for incentivizing its management team.
Employment Agreement - CEO
On June
2, 2022, the Board approved an Employment Agreement with the CEO dated effective April 1, 2022 whereby, the CEO will receive an annual
salary of $100,000 which accrues unless converted into shares of common stock of the Company at a stipulated conversion rate. If the Company
reaches $1,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $150,000 commencing the following month.
If the Company reaches $5,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $200,000 commencing the
following month. The Company awarded the CEO an aggregate of 7,000,000 shares of the Company’s common stock under the 2022 Stock
Incentive Plan, which will vest (i) 1,500,000 shares on April 1, 2023, (ii) 2,500,000 shares on April 1, 2024, and
(iii) 3,000,000 shares on April 1, 2025. The shares are valued at the 90% of the average market price of the shares of 30 trading
days at the end of each quarter. The Company has recorded $142,424 in salaries payable to the CEO as of March 31, 2023 and December 31,
2022, respectively.
Employment Agreement – COO/Interim CFO
On June 2, 2022, the Board approved an Employment
Agreement with the COO/Interim CFO dated effective April 1, 2022, whereby, the officer will receive an annual salary of $100,000 which
accrues unless converted into shares of common stock of the Company at a stipulated conversion rate. If the Company reaches $1,000,000
in cumulative sales over a 12-month period, the annual salary will increase to $150,000 commencing the following month. If the Company
reaches $5,000,000 in cumulative sales over a 12-month period, the annual salary will increase to $200,000 commencing the following month.
The Company awarded the COO/Interim CFO an aggregate of 7,000,000 shares of the Company common stock under the 2022 Stock Incentive
Plan, which will vest (i) 1,500,000 shares on April 1, 2023, (ii) 2,500,000 shares on April 1, 2024, and (iii) 3,000,000 shares
on April 1, 2025. The shares are valued at the 90% of the average market price of the shares of
30 trading days at the end of each quarter. The Company recorded $121,092 in salaries payable to the COO/Interim CFO as of March
31, 2023 and December 31, 2022, respectively.
NOTE 6 - CONVERTIBLE NOTES PAYABLE
The following table summarizes the outstanding
balance of convertible notes payable, interest and conversion rates as of March 31, 2023 and December 31, 2022, respectively.
| |
Schedule of convertible notes payable | |
| | |
| |
| |
| |
March 31,
2023 | | |
December 31, 2022 | |
| |
| |
| | |
| |
A. | |
Convertible note payable to an investor with interest at 12% per annum, convertible at any time into shares of common stock at $0.008 per share. The balance of principal and accrued and unpaid interest is payable on maturity on March 1, 2023, unless automatically extended for one-year periods if no Event of Default is existing. The note is secured by substantially all the assets of the Company. | |
$ | 205,000 | | |
$ | 205,000 | |
| |
| |
| | | |
| | |
B. | |
Convertible note payable to an investor with interest at 5% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable annually with the balance of principal and interest due on maturity on March 1, 2024. The note is secured by substantially all the assets of the Company. | |
| 55,000 | | |
| 55,000 | |
| |
| |
| | | |
| | |
D. | |
Convertible note payable to an investor with interest at 12% per annum, convertible at any time into shares of common stock at $0.008 per share. The balance of principal and accrued and unpaid interest is payable on March 1, 2023, unless automatically extended for one-year periods if no Event of Default is existing. The note is secured by substantially all the assets of the Company. | |
| 50,000 | | |
| 50,000 | |
| |
| |
| | | |
| | |
E. | |
Convertible notes payable to a related party with interest at 12% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on August 2, 2024. The notes are secured by substantially all the assets of the Company. | |
| 125,000 | | |
| 125,000 | |
| |
| |
| | | |
| | |
F. | |
Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock originally at $0.01 per share. Principal and interest due on maturity on April 29, 2023. | |
| 7,353 | | |
| 33,167 | |
| |
| |
| | | |
| | |
G. | |
Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock originally at $0.0099 per share. Note was issued as payment for future fees to be incurred under the related Equity Financing Agreement. Principal and interest due on maturity on April 29, 2025. | |
| 75,000 | | |
| 75,000 | |
| |
| |
| | | |
| | |
| |
| |
| 517,353 | | |
| 543,167 | |
| |
Less: deferred financing costs | |
| (75,700 | ) | |
| (75,700 | ) |
| |
Less unamortized discount | |
| – | | |
| – | |
| |
Net balance | |
| 441,653 | | |
| 467,467 | |
| |
Less current portion | |
| (392,353 | ) | |
| (363,167 | ) |
| |
Long term portion | |
$ | 49,300 | | |
$ | 104,300 | |
A. January 18, 2018 Convertible Note and Warrants (“Note
A”)
On March 14, 2022, the noteholder of Note A agreed
to extend the maturity date of March 1, 2022 of the Senior Secured Convertible Promissory Note to March 1, 2023, in exchange for the reduction
of the conversion price to $0.008 per share, and all prior Events of Default (as defined in the Note A) including penalties were waived,
and all future Events of Default (as defined in the Note A) pertaining to the future payment of interest were waived through maturity.
The Company is in default with the terms of the Note A and is currently negotiating with the noteholder to extend the maturity date to
cure the default.
The Company recorded interest expense of $6,066
and $8,729 for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note A was $165,934 and $159,868
as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable on Note A amounted
to $205,000 on March 31, 2023 and December 31, 2022, respectively.
B. January 2019 Convertible Note and Warrants (“Note
B”)
Effective March 1, 2021, the noteholder of Note
B agreed to extend the maturity date of March 1, 2021 of the Secured Convertible Promissory Note to March 1, 2024, and all prior Events
of Default (as defined in the Note B) including penalties were waived, and all other terms of the Note B remain the same (Note 9).
The Company recorded interest expense of $678
and $678 on Note B for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note B was $11,520 and
$10,842 as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable on Note B amounted
to $55,000 and $55,000 on March 31, 2023 and December 31, 2022, respectively.
D. March 2019 Convertible Note and Warrants
(“Note D”)
On March 14, 2022, the noteholder of Note D agreed
to extend the maturity date of March 1, 2022 of the Senior Secured Convertible Promissory Note to March 1, 2023, in exchange for the reduction
of the conversion price to $0.008 per share, and all prior Events of Default (as defined in the Note D) including penalties were waived,
and all future Events of Default (as defined in the Note D) pertaining to the future payment of interest were waived through maturity.
The Company is in default with the terms of the Note D and is currently negotiating with the noteholder to extend the maturity date to
cure the default.
The Company recorded interest expense of $1,479
and $1,479 on Note D for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note D was $22,177
and $20,698 as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable on Note D amounted
to $50,000 on March 31, 2023 and December 31, 2022, respectively.
E. August 2019 Convertible Note and Warrants (“Note
E”)
On August 2, 2021, the noteholder of Note E agreed
to extend the maturity date of the Secured Convertible Promissory Note to August 2, 2024. All other terms and conditions of the Note E
remain the same.
The Company recorded interest expense of $3,699
and $3,699 on Note E for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note E was $52,389
and $48,690 as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable on Note E amounted
to $125,000 and $125,000 on March 31, 2023 and December 31, 2022, respectively.
F. July 2020 Equity Financing Arrangement
(“Note F”)
On April 29, 2022, the noteholder of Note F agreed
to extend the maturity date of the Secured Convertible Promissory Note to April 29, 2023. All other terms and conditions of the Note F
remain the same. On March 23, 2023, the noteholder of Note F converted the principal balance of its convertible promissory note of $25,814
and $7,186 of accrued interest into 17,837,838 shares of common stock of the Company valued at the fair value of $0.00185 per share.
The Company recorded interest expense of $757
and $818 on Note F for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note F was $0 and $5,029
as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable on Note F amounted
to $7,353 and $33,167 on March 31, 2023 and December 31, 2022, respectively.
G . July 2020 Equity Financing Arrangement
(“Note G”)
On April 29, 2022, the noteholder of Note G agreed
to extend the maturity date of the Secured Convertible Promissory Note to April 29, 2023. All other terms and conditions of the Note G
remain the same.
The Company recorded interest expense of $1,849
and $1,849 on Note G for the three months ended March 31, 2023 and 2022, respectively. Accrued interest payable on Note G was $17,688
and $17,240 as of March 31, 2023 and December 31, 2022, respectively.
The principal balance payable of Note G amounted
to $75,000 at March 31, 2023 and December 31, 2022, respectively.
NOTE 7 - EARNINGS (LOSS) PER SHARE
The following table sets forth the computation
of basic and diluted net loss per share of common stock for the three months ended March 31, 2023 and 2022:
Schedule of earnings per share | |
| | |
| |
| |
Three Months Ended March 31, | |
| |
2023 | | |
2022 | |
Net loss attributable to common stockholders (basic) | |
$ | (178,170 | ) | |
$ | (525,160 | ) |
| |
| | | |
| | |
Shares used to compute net loss per common share, basic and diluted | |
| 374,217,262 | | |
| 224,759,740 | |
| |
| | | |
| | |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
Basic net loss per share is calculated by dividing
net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing
net loss by the weighted-average number of common shares and common share equivalents outstanding for the period. Common stock equivalents
are only included when their effect is dilutive. The Company’s potentially dilutive securities which include stock options, convertible
debt, convertible preferred stock and common stock warrants have been excluded from the computation of diluted net loss per share as they
would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares
outstanding due to the Company’s net loss position.
The following outstanding common stock equivalents
have been excluded from diluted net loss per common share for the three months ended March 31, 2023 and 2022, respectively, because their
inclusion would be anti-dilutive:
Schedule of anti dilutive shares | |
| | |
| |
| |
As of March 31, | |
| |
2023 | | |
2022 | |
Warrants to purchase common stock | |
| 2,868,397 | | |
| 2,868,397 | |
Potentially issuable shares related to convertible notes payable and convertible preferred stock | |
| 370,172,003 | | |
| 347,878,284 | |
Total anti-dilutive common stock equivalents | |
| 373,040,400 | | |
| 350,741,681 | |
NOTE 8 - RELATED PARTIES
At March 31, 2023 and December 31, 2022, respectively,
the amount due to two stockholders was $1,000 relating to depositing funds for opening bank accounts for the Company.
The Company executed an operating lease to rent
its current office facility from a stockholder on a month-to-month basis at a monthly rent of $250 starting January 1, 2020. The Company
recorded rent expense of $750 for the three months ended March 31, 2023 and 2022, respectively. The Company has recorded $1,000 and $250
of rent payable to the stockholder in accounts payable as of March 31, 2023 and December 31, 2022, respectively.
NOTE 9 - STOCKHOLDERS' EQUITY
The Company
has an authorized capital of 1,000,000,000 shares, $0.001 par value common stock, and 10,000,000 shares of $0.001 par value preferred
stock at March 31, 2023. The Company has 401,865,785 shares 352,174,583 shares of common stock, and 25,845 shares and 25,845 shares of
preferred stock, issued and outstanding as of March 31, 2023 and December 31, 2022, respectively.
Common Stock
Holders of shares of common stock are entitled
to one vote for each share on all matters to be voted on by the stockholders. Holders of common stock do not have cumulative voting rights.
Holders of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors
in its discretion from funds legally available, therefore. In the event of liquidation, dissolution, or winding up of the Company, the
holders of common stock are entitled to share pro rata in all assets remaining after payment in full of all liabilities. All of the outstanding
shares of common stock are fully paid and non-assessable. Holders of common stock have no preemptive rights to purchase the Company’s
common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock.
On February 24, 2021, the Company entered into
a Common Stock Purchase Agreement with an investor pursuant to which the investor agreed to purchase up to $5,000,000 of the Company’s
registered common stock at $0.015 per share. Pursuant to the Agreement, purchases may be made by the Company during the Commitment Period
(as defined in the Agreement) through the submission of a purchase notice to the investor no sooner than ten business days after the preceding
closing. No purchase notice can be made in an amount less than $10,000 or greater than $500,000 or greater than two times the average
of the daily trading dollar volume for the Company’s common stock during the ten business days preceding the purchase date. Each
purchase notice is limited to the investor beneficially owning no more than 4.99% of the total outstanding common stock of the Company
at any given time. There are certain conditions precedent to each purchase including, among others, an effective registration statement
in place and the VWAP of the closing price of the Company’s common stock greater than $0.0175 for the Company's common stock during
the five business days prior to the closing. From January 1, 2023 to March 31, 2023, the investor purchased 31,603,364 shares of common
stock for a cash consideration of $54,196.
On February 10, 2023, the Company issued 50,000
shares of its common stock to a consultant for services. The common stock was valued at the fair market price of $215 on the date of issuance.
The shares were issued under the Company’s 2019 Stock Incentive Plan.
On February 21, 2023, the Company issued 100,000
shares of its common stock to a consultant for services. The common stock was valued at the fair market price of $340 on the date of issuance.
The shares were issued under the Company’s 2019 Stock Incentive Plan.
On March 13, 2023, the Company issued 100,000
shares of its common stock to a consultant for services. The common stock was valued at the fair market price of $270 on the date of issuance.
The shares were issued under the Company’s 2019 Stock Incentive Plan.
On March 23, 2023, the noteholder of Note F converted
the principal balance of $25,814 and accrued interest of $7,186 into 17,837,838 shares of common stock. The shares issued were valued
at the fair value of common stock on the date of issuance.
Stock Incentive Plans
On December 14, 2017, the Board of Directors of
the Company approved the 2017 Stock Incentive Plan (the “2017 Plan”). Awards may be made under the 2017 Plan for up
to 4,500,000 shares of common stock of the Company. All of the Company’s employees, officers and directors, as well as consultants
and advisors to the Company are eligible to be granted awards under the 2017 Plan. No awards can be granted under the 2017 Plan after
the expiration of 10 years from the plan approval but awards previously granted may extend beyond that date. Awards may consist of both
incentive and non-statutory options, restricted stock units, stock appreciation rights, and restricted stock awards.
On March 11, 2019, the Board of Directors of the
Company approved the 2019 Stock Incentive Plan (the “2019 Plan”). Awards may be made under the 2019 Plan for up to
5,000,000 shares of common stock of the Company. All of the Company’s employees, officers and directors, as well as consultants
and advisors to the Company are eligible to be granted awards under the 2019 Plan. No awards can be granted under the 2019 Plan after
the expiration of 10 years from the plan approval but awards previously granted may extend beyond that date. Awards may consist of both
incentive and non-statutory options, restricted stock units, stock appreciation rights, and restricted stock awards.
On March 18, 2022, the Board of Directors
approved and adopted the 2022 Stock Incentive Plan (the “2022 Plan”). Awards may be made under the 2022 Plan for
up to 20,000,000
shares of common stock of the Company, subject to adjustment as to the number and kind of shares awarded. Only employees and
directors of the Company or an Affiliated company are eligible to receive Incentive Options under the 2022 Plan. The Company awarded 7,000,000
shares of the Company’s common stock to an officer and 7,000,000
shares of common stock to a director of the Company (see Note 4) vesting 1,500,000 shares vesting on the first anniversary on the
date of issuance, 2,500,000 shares vesting on the second anniversary of the date of issuance, and 3,000,000 shares on the third
anniversary of the date of issuance. In addition, on October 3, 2022, the Company awarded
300,000
shares of common stock to an advisor vesting 100,000 shares on the first anniversary date of issuance, 100,000 shares vesting on the
second anniversary, and the remaining 100,000 vesting the third anniversary of the date of issuance. The common shares vested
pursuant to the 2022 Plan amounted to 0
shares at March 31, 2023 and December 31, 2022, and the 14,300,000
remain unvested as of March 31, 2023. For the three months March 31, 2023, the Company recorded $1,735
as stock compensation expense for the 739,726
shares payable to an officer and a director that remain unvested as of March 31, 2023. Total shares payable to an officer,
consultant and a director totaled 3,308,219
shares and 2,568,493
shares at March 31, 2023 and December 31, 2022, respectively.
Shares earned and issued related to the consulting
agreements are issued under the 2017 Stock Incentive Plan and the 2019 Stock Incentive Plan (Note 4). Vesting of the shares is subject
to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as defined in the agreement) or the listing
of the Company’s common stock on a senior exchange.
A summary of the status of the Company’s
non-vested shares as of March 31, 2023 and 2022, and changes during the three months period then ended, is presented below:
Schedule of summary of non-vested shares | |
| | |
| |
2022 Plan | |
Non-vested Shares of Common Stock | | |
Weighted Average
Fair Value | |
Authorized shares per the 2022 Plan – 20,000,000 shares | |
| | | |
| | |
Balance at December 31, 2022 | |
| 14,300,000 | | |
$ | 0.006146 | |
Awarded | |
| – | | |
| – | |
Vested | |
| – | | |
| – | |
Forfeited | |
| – | | |
| – | |
Balance at March 31, 2023 | |
| 14,300,000 | | |
$ | – | |
| |
| | | |
| | |
2019 Plan | |
| | | |
| | |
Authorized shares per the 2019 Plan – 5,000,000 shares | |
| | | |
| | |
Balance at December 31, 2022 | |
| – | | |
$ | 0.30 | |
Awarded | |
| – | | |
| – | |
Vested | |
| – | | |
| – | |
Forfeited | |
| – | | |
| – | |
Balance at March 31, 2023 | |
| – | | |
$ | 0.30 | |
| |
|
| | |
|
| |
2017 Plan | |
|
| | |
|
| |
Authorized shares per the 2017 Plan – 4,500,000 shares | |
|
| | |
|
| |
Balance at December 31, 2022 | |
| – | | |
$ | 0.30 | |
Awarded | |
| – | | |
| – | |
Vested | |
| – | | |
| – | |
Forfeited | |
| – | | |
| – | |
Balance at March 31, 2023 | |
| – | | |
$ | 0.30 | |
Preferred Stock
Series A Supervoting Convertible Preferred
Stock
On July 2, 2020, the Board of Directors of the
Company authorized the issuance of 15,600 shares of preferred stock, $0.001 par value per share, designated as Series A Supervoting Convertible
Preferred Stock.
Dividends: Initially, there will be
no dividends due or payable on the Series A Supervoting Preferred Stock. Any future terms with respect to dividends shall be determined
by the Board consistent with the Corporation’s Articles of Incorporation.
Liquidation and Redemption Rights: Upon
the occurrence of a Liquidation Event (as defined below), the holders of Series A Supervoting Preferred Stock are entitled to receive
net assets on a pro-rata basis. Each holder of Series A Supervoting Preferred Stock is entitled to receive ratably any dividends declared
by the Board, if any, out of funds legally available for the payment of dividends. Liquidation Event means (i) the liquidation, dissolution
or winding-up, whether voluntary or involuntary, of the corporation, (ii) the purchase or redemption by the corporation of the shares
of any class of stock or the merger or consolidation of the corporation with or into any other corporation or corporations, or (iii) the
sale, license or lease of all or substantially all, or any material part of, the Corporation’s assets.
Conversion: Each holder of Series
A Supervoting Preferred Stock may voluntarily convert its shares into shares of common stock of the Corporation at a rate of 1:100 (as
may be adjusted for any combinations or splits with respect to such shares).
Rank: All shares of the Series A Supervoting
Preferred Stock shall rank senior to the Corporation’s (A) common stock, par value $0.001 per share, and any other class or series
of capital stock of the Corporation hereafter created.
Voting Rights:
|
A. |
If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting. |
|
|
|
|
B. |
Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to: |
[twenty times the sum of: {all
shares of Common stock issued and outstanding at the time of voting + all shares of Series A and any newly designated Preferred stock
issued and outstanding at the time of voting}]
Divided by:
[the number of shares of Series
A Super Voting Preferred Stock issued and outstanding at the time of voting]
With respect to all matters upon which
stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares
of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to
those matters on which separate class voting is required by applicable law or the Articles of Incorporation or Bylaws.
The Company had 25,845 shares of preferred stock
issued and outstanding at March 31, 2023 and December 31, 2022, respectively.
Series B Convertible Preferred Stock Equity
Financing
On November 16, 2020, the Board of Directors of
the Company authorized the issuance of up to 600 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible
Preferred Stock. Each share of Preferred Stock has a par value of $0.001 per share and a stated value of $1,200, subject to increase set
forth in the Certificate of Designation.
Dividends: Each share of Series B
Convertible Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 12% per annum, payable
quarterly, beginning on the Original Issuance Date and ending on the date that such share of Series B Convertible Preferred Share has
been converted or redeemed (the “Dividend End Date”). Dividends may be paid in cash or in shares of Series B Convertible Preferred
Stock. From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be
entitled to receive, and the Corporation shall pay, dividends on shares of Series B Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock
basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares
of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous
sentence.
Voting Rights: The Series B Convertible
Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not
in excess of 4.99% conversion limitation). However, as long as any shares of Series B Convertible Preferred Stock are outstanding, the
Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series B Convertible
Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Convertible
Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption
or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series B Convertible
Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series
B Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects
any rights of the Holders, (d) increase the number of authorized shares of Series B Convertible Preferred Stock, or (e) enter into any
agreement with respect to any of the foregoing.
Liquidation: Upon any liquidation,
dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled
to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and
unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for
each share of Series B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities,
and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the
Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares
if all amounts payable thereon were paid in full.
Conversion: Each share of Series B
Convertible Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value
of such share of Series B Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series B Convertible Preferred
Stock shall be the amount equal to the lowest traded price for the Company’s common stock for the fifteen (15) Trading Days immediately
preceding the date of such conversion. All such foregoing determinations will be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the common stock during
such measuring period. Following an event of default, the Conversion price shall equal the lower of: (a) the then applicable Conversion
Price; or (b) a price per share equaling 80% of the lowest traded price for the Company’s common stock during the ten (10) trading
days preceding the relevant Conversion.
Redemption: The Series B Convertible Preferred
Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.
|
· |
115% of the stated value if the redemption takes place within 90 days of issuance; |
|
· |
120% of the stated value if the redemption takes place after 90 days and within 120 days of issuance |
|
· |
125% of the stated value if the redemption takes place after 120 days and within 180 days of issuance; and |
|
· |
each share of Preferred Stock is redeemed one year from the day of issuance |
November 19, 2020
On November 19, 2020, pursuant to the terms of
a Securities Purchase Agreement dated November 16, 2020 (the “SPA”), the Company entered into a new preferred equity financing
agreement with GHS Investments, LLC (“GHS”) in the amount of up to $600,000. The SPA provides for GHS’s purchase, from
time to time, of up to 600 shares of the newly-designated Series B Convertible Preferred Stock. The initial closing under the SPA consisted
of 45 shares of Series B Convertible Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $45,000,
or $1,000 per share. At the Company’s option, and subject to the terms of the SPA and the Certificate of Designation for the Series
B Convertible Preferred Stock (the “COD”), additional closings in the amount of 40 shares of Series B Convertible Preferred
Stock for a total purchase price of $40,000 may take place at a rate of up to once every 30 days. In connection with the initial closing
in the amount of 45 shares of Series B Convertible Preferred Stock, the Company issued an additional 25 shares of Series B Convertible
Preferred Stock to GHS as a commitment fee.
No additional closings may take place after the
two-year anniversary of the SPA, or once the entire $600,000 amount has been funded. If the average daily dollar trading volume for the
Company’s common stock for the 30 trading days preceding a particular additional closing is at least $50,000 per day, the Company
may, at its option, increase the amount of that additional closing to 75 shares of Series B Convertible Preferred Stock ($75,000).
The Series B Convertible Preferred Stock is classified
as temporary equity, as it is convertible upon issuance at an amount equal to the lowest traded price for the Company’s common stock
for the fifteen trading days immediately preceding the date of conversion.
Based on the requirements of ASC 815, Derivatives
and Hedging, the conversion feature represents an embedded derivative that is required to be bifurcated and accounted for as a separate
derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each
conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting
period.
On November 19, 2020, GHS purchased a total of
70 shares of Series B Convertible Preferred Stock for gross proceeds of $45,000. The Company paid $900 in selling commissions to complete
this financing.
On November 19, 2020 (the date of receipt of cash
proceeds of $45,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $103,267,
$58,267 as day one loss on the derivative, $39,000 as interest expense, and $39,000 as Series B Convertible Preferred Stock mezzanine
liability, and $45,000 as amortization.
The Company recalculated the value of the derivative
liability associated with this convertible preferred stock recording a loss of $199 and a gain of $18,069 for the three months ended March
31, 2023 and 2022 in connection with the change in fair market value of the derivative liability. The Company recorded $2,485 as preferred
stock dividend expense for the three months ended March 31, 2023 and 2022, and $23,805 and $21,320 as preferred stock dividend payable
as of March 31, 2023 and December 31, 2022, respectively. Derivative liability payable for this transaction totaled $72,665 and $72,456
at March 31, 2023 and December 31, 2022, and Series B Convertible Preferred Stock mezzanine liability was $84,000 at March 31, 2023 and
December 31, 2022, respectively.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0140, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.0015 to $0.0184, an expected dividend yield
of 0%, expected volatility ranging from 160.41% to 440.99%, risk-free interest rates ranging from 0.38% to 4.73%, and an expected term
ranging from 0.13 years to 1.50 years.
December 16, 2020
On December 16, 2020, pursuant to the terms of
the SPA, GHS purchased an additional 85 shares of Series B Convertible Preferred Stock for gross proceeds of $85,000. The Company paid
$1,700 in selling commissions to complete this financing.
On December 16, 2020 (the date of receipt of cash
proceeds of $85,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $106,241,
$21,241 as day one loss on the derivative, $17,000 as interest expense, and $17,000 as Series B Convertible Preferred Stock mezzanine
liability, and $85,000 as amortization.
The Company recalculated the value of the derivative
liability associated with this convertible preferred stock recording a loss of $242 and a gain of $20,784 for the three months ended March
31, 2023 and 2022 in connection with the change in fair market value of the derivative liability. The Company recorded $3,018 as preferred
stock dividend expense for the three months ended March 31, 2023 and 2022, and $28,001 and $24,983 as preferred stock dividend payable
as of March 31, 2023 and December 31, 2022, respectively. Derivative liability payable for this transaction totaled $88,224 and 87,982
at March 31, 2023 and December 31, 2022, and Series B Convertible Preferred Stock mezzanine liability was $102,000 at March 31, 2023 and
December 31, 2022, respectively.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0187, the
closing stock price of the Company's common stock on the date of valuation ranging from $0.0015 to $0.0184, an expected dividend yield
of 0%, expected volatility ranging from 160.41% to 431.65%, risk-free interest rates ranging from 0.38% to 4.737%, and an expected term
of 1.50 years.
December 20, 2021
On December 20, 2021, pursuant to the terms of
the SPA, GHS purchased an additional 51 shares of Series B Convertible Preferred Stock for gross proceeds of $51,000. The Company paid
$1,000 in selling commissions to complete this financing.
The Company recalculated the value of the derivative
liability associated with this convertible preferred stock recording a loss of $145 for the three months ended March 31, 2023 in connection
with the change in fair market value of the derivative liability. The Company recorded $1,811 as preferred stock dividend expense for
the three months ended March 31, 2023 and 2022, and $9,376 and $7,565 as preferred stock dividend payable as of March 31, 2023 and December
31, 2022, respectively. Derivative liability payable for this transaction totaled $52,935 and $52,789 at March 31, 2023 and December 31,
2022 and Series B Convertible Preferred Stock mezzanine liability was $61,200 at March 31, 2023 and December 31, 2022, respectively.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0050 the
closing stock price of the Company's common stock on the date of valuation ranging from $0.0015 to $0.0060, an expected dividend yield
of 0%, expected volatility ranging from 174.58% to 208.19%, risk-free interest rates ranging from 0.91% to 4.737%, and an expected term
of 1.50 years.
February 7, 2022
On February 7, 2022, pursuant to the terms of
the SPA, GHS purchased an additional 51 shares of Series B Convertible Preferred Stock for gross proceeds of $51,000. The Company paid
$1,000 in selling commissions to complete this financing.
On February 7, 2022 (the date of receipt of cash
proceeds of $51,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $65,025,
$14,025 as day one loss on the derivative, $10,200 as interest expense, and $10,200 as Series B Convertible Preferred Stock mezzanine
liability, and $51,000 as amortization.
The Company recalculated the value of the
derivative liability associated with the convertible note at March 31, 2023 and 2022, and recorded a loss of $145
and $16,928
for the three months ended March 31, 2023 and 2022, respectively, in connection with the change in fair market value of the
derivative liability. In addition, the Company recorded $1,811
and $1,046
as preferred stock dividend expense for the three months ended March 31, 2023 and 2022. Preferred stock dividend payable to GHS on
this derivative totaled $8,390
and $6,579
as of March 31, 2023 and December 31, 2022. Derivative liability payable for this transaction totaled $52,935
and $52,789
at March 31, 2023 and December 31, 2022, and Series B Convertible Preferred Stock mezzanine liability was $61,200
at March 31, 2023 and December 31, 2022, respectively.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0096, the
closing stock price of the Company’s common stock on the date of valuation ranging from $0.0015 to $0.0172, an expected dividend yield
of 0%, expected volatility ranging from 160.35% to 177.44%, risk-free interest rates ranging from 1.09% to 4.73%, and an expected term
of 1.35 to 1.5 years.
March 24, 2022
On March 24, 2022, pursuant to the terms of the
SPA, GHS purchased an additional 136 shares of Series B Convertible Preferred Stock for gross proceeds of $136,000. The Company paid $2,720
in selling commissions to complete this financing.
On March 24, 2022 (the date of receipt of cash
proceeds of $136,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $328,422,
$192,422 as day one loss on the derivative, $27,200 as interest expense, and $27,200 as Series B Convertible Preferred Stock mezzanine
liability, and $136,000 as amortization.
The Company recalculated the value of the derivative
liability associated with the convertible note at March 31, 2023 and 2022, and recorded a loss of $387 and a gain of $105,194 for the
three months ended March 31, 2023 and 2022, respectively, in connection with the change in fair market value of the derivative liability.
In addition, the Company recorded preferred stock dividend expense of $4,829 and $376 for the three months ended March 31, 2023 and 2022.
Preferred stock dividend payable to GHS for this derivative totaled $19,960 and $15,131 at March 31, 2023 and December 31, 2022. Derivative
liability payable for this transaction totaled $141,159 and $140,772 at March 31, 2023 and December 31, 2022, respectively, and Series
B Convertible Preferred Stock mezzanine liability was $163,200 at March 31, 2023 and December 31, 2022.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0096, the
closing stock price of the Company’s common stock on the date of valuation ranging from $0.0015 to $0.0183, an expected dividend yield
of 0%, expected volatility ranging from 160.35% to 177.44%, risk-free interest rates ranging from 1.55% to 4.73%, and an expected term
of 1.48 to 1.5 years.
November 17, 2022
On November 17, 2022, pursuant to the terms of
the SPA, GHS purchased an additional 61 shares of Series B Convertible Preferred Stock for gross proceeds of $61,000. The Company paid
$1,220 in selling commissions to complete this financing.
On November 17, 2022 (the date of receipt of cash
proceeds of $61,000 issuance), the Company valued the fair value of the derivative and recorded an initial derivative liability of $54,072,
$6,928 as day one gain on the derivative, $12,200 as interest expense, and $12,200 as Series B Convertible Preferred Stock mezzanine liability,
and $61,000 as amortization.
The Company recalculated the value of the derivative
liability associated with the convertible note at March 31, 2023 and recorded a loss of $174 for the three months ended March 31, 2023,
in connection with the change in fair market value of the derivative liability. In addition, the Company recorded preferred stock dividend
expense of $2,166 for the three months ended March 31, 2023. Preferred stock dividend payable to GHS for this derivative totaled $3,225
and $1,059 at March 31, 2023 and December 31, 2022. Derivative liability payable for this transaction totaled $63,314 and $63,140 at March
31, 2023 and December 31, 2022, respectively, and Series B Convertible Preferred Stock mezzanine liability was $73,200 at March 31, 2023
and December 31, 2022.
The Company valued the conversion feature using
the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $0.0013 to $0.0020, the
closing stock price of the Company’s common stock on the date of valuation ranging from $0.0015 to $0.0022, an expected dividend yield
of 0%, expected volatility ranging from 174.58% to 179.98%, risk-free interest rates ranging from 4.64% to 4.73%, and an expected term
of 1.5 years.
As a result of issuance of derivative instruments,
the Company recorded a derivative liability of $471,165 and $469,873 as of March 31, 2023 and December 31, 2022, and Series B Convertible
Preferred Stock liability of $544,800 as of March 31, 2023 and December 31, 2022, respectively.
Warrants
A summary of the status of the Company’s
warrants as of March 31, 2023 and 2022, and changes during the three months then ended, is presented below:
Schedule of summary of warrant activity | |
| | |
| | |
| |
| |
Shares Under Warrants | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Life | |
Outstanding at December 31, 2021 | |
| – | | |
| – | | |
| | |
Issued | |
| 2,868,397 | | |
$ | 0.00084 | | |
| 2.4 Years | |
Exercised | |
| – | | |
| – | | |
| | |
Expired/Forfeited | |
| – | | |
| – | | |
| | |
Outstanding at March 31, 2022 | |
| 2,868,397 | | |
$ | 0.00084 | | |
| 2.2 Years | |
| |
| | | |
| | | |
| | |
Outstanding at December 31, 2022 | |
| – | | |
| – | | |
| | |
Issued | |
| 2,868,397 | | |
$ | 0.00084 | | |
| 1.4 Years | |
Exercised | |
| – | | |
| – | | |
| | |
Expired/Forfeited | |
| – | | |
| – | | |
| | |
Outstanding at March 31, 2023 | |
| 2,868,397 | | |
$ | 0.00084 | | |
| 1.2 Years | |
NOTE 10 – SUBSEQUENT EVENTS
Management has evaluated subsequent events through
the date of this Report, the date the financial statements were available to be issued, noting the following items that would impact the
accounting for events or transactions in the current period or require additional disclosure.
On April 27, 2023, the noteholder of Note F elected
to convert $7,353 of principal amount and $71 of accrued interest, totaling $7,424 into 4,949,507 shares of common stock. The shares were
valued at the fair value of the common stock on the date of issuance.
On May 1, 2023, the noteholder of Note G agreed
to extend the maturity date of the Convertible Promissory Note G to April 29, 2025. All other terms and conditions of the convertible
promissory note remain the same.